We are a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Our initial therapeutic focus is in oncology, where pivotal clinical trials are currently underway for our lead program, tebentafusp (IMCgp100), as a potential treatment for metastatic uveal melanoma, a rare form of eye cancer.

We also have a robust pipeline of programs spanning a broad range of cancer indications, as well as infectious and autoimmune diseases.